Logo image of BDMD

BAIRD MEDICAL INVESTMENT HOL (BDMD) Stock Fundamental Analysis

USA - NASDAQ:BDMD - KYG0705H1039 - Common Stock

1.59 USD
-0.15 (-8.62%)
Last: 10/8/2025, 8:00:01 PM
1.55 USD
-0.04 (-2.52%)
Pre-Market: 10/9/2025, 6:36:25 AM
Fundamental Rating

3

BDMD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. BDMD has only an average score on both its financial health and profitability. BDMD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year BDMD was profitable.
BDMD had a negative operating cash flow in the past year.
In multiple years BDMD reported negative net income over the last 5 years.
BDMD had a negative operating cash flow in each of the past 5 years.
BDMD Yearly Net Income VS EBIT VS OCF VS FCFBDMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

1.2 Ratios

BDMD's Return On Assets of 16.04% is amongst the best of the industry. BDMD outperforms 96.34% of its industry peers.
The Return On Equity of BDMD (31.53%) is better than 98.43% of its industry peers.
Looking at the Return On Invested Capital, with a value of 22.61%, BDMD belongs to the top of the industry, outperforming 98.43% of the companies in the same industry.
Industry RankSector Rank
ROA 16.04%
ROE 31.53%
ROIC 22.61%
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BDMD Yearly ROA, ROE, ROICBDMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

Looking at the Profit Margin, with a value of 33.76%, BDMD belongs to the top of the industry, outperforming 97.38% of the companies in the same industry.
BDMD has a better Operating Margin (41.35%) than 100.00% of its industry peers.
The Gross Margin of BDMD (88.17%) is better than 97.38% of its industry peers.
Industry RankSector Rank
OM 41.35%
PM (TTM) 33.76%
GM 88.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDMD Yearly Profit, Operating, Gross MarginsBDMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BDMD is creating value.
Compared to 1 year ago, BDMD has less shares outstanding
Compared to 1 year ago, BDMD has a worse debt to assets ratio.
BDMD Yearly Shares OutstandingBDMD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
BDMD Yearly Total Debt VS Total AssetsBDMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 2.74 indicates that BDMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
BDMD's Altman-Z score of 2.74 is fine compared to the rest of the industry. BDMD outperforms 66.49% of its industry peers.
BDMD has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
BDMD has a Debt to Equity ratio of 0.49. This is comparable to the rest of the industry: BDMD outperforms 43.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z 2.74
ROIC/WACC3.63
WACC6.23%
BDMD Yearly LT Debt VS Equity VS FCFBDMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

BDMD has a Current Ratio of 1.77. This is a normal value and indicates that BDMD is financially healthy and should not expect problems in meeting its short term obligations.
BDMD's Current ratio of 1.77 is on the low side compared to the rest of the industry. BDMD is outperformed by 68.59% of its industry peers.
A Quick Ratio of 1.74 indicates that BDMD should not have too much problems paying its short term obligations.
The Quick ratio of BDMD (1.74) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.74
BDMD Yearly Current Assets VS Current LiabilitesBDMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

BDMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.58%, which is quite good.
Looking at the last year, BDMD shows a quite strong growth in Revenue. The Revenue has grown by 17.74% in the last year.
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.58%
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDMD Yearly Revenue VS EstimatesBDMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 10M 20M 30M

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 3.31, the valuation of BDMD can be described as very cheap.
98.43% of the companies in the same industry are more expensive than BDMD, based on the Price/Earnings ratio.
BDMD is valuated cheaply when we compare the Price/Earnings ratio to 27.91, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 3.31
Fwd PE N/A
BDMD Price Earnings VS Forward Price EarningsBDMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BDMD is valued cheaply inside the industry as 98.95% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.5
BDMD Per share dataBDMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BDMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BAIRD MEDICAL INVESTMENT HOL

NASDAQ:BDMD (10/8/2025, 8:00:01 PM)

Premarket: 1.55 -0.04 (-2.52%)

1.59

-0.15 (-8.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-15 2025-05-15
Earnings (Next)N/A N/A
Inst Owners2.11%
Inst Owner ChangeN/A
Ins Owners71.59%
Ins Owner ChangeN/A
Market Cap40.64M
AnalystsN/A
Price TargetN/A
Short Float %346.5%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 3.31
Fwd PE N/A
P/S 1.1
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.03
EV/EBITDA 2.5
EPS(TTM)0.48
EY30.19%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS1.45
BVpS1.55
TBVpS1.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 16.04%
ROE 31.53%
ROCE 35.34%
ROIC 22.61%
ROICexc 23.79%
ROICexgc 23.82%
OM 41.35%
PM (TTM) 33.76%
GM 88.17%
FCFM N/A
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA 1.17
Cap/Depr 189.31%
Cap/Sales 7.7%
Interest Coverage 30.8
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.77
Quick Ratio 1.74
Altman-Z 2.74
F-Score3
WACC6.23%
ROIC/WACC3.63
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.58%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-150.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-518.93%
OCF growth 3YN/A
OCF growth 5YN/A